The Venture Codex

Participated · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.

Participated · Series A · Dec 2025

TargED Biopharmaceuticals B.V., founded in 2020 as a spin-out from University Medical Center Utrecht, is focused on TGD001, an antibody-enzyme fusion protein that binds von Willebrand factor (VWF) and degrades both VWF and fibrin to dissolve clots. The therapy has completed a Phase 1 first-in-human study that showed a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. With its latest funding, the company will initiate two Phase 1/2 clinical studies targeting acute ischemic stroke and thrombotic microangiopathies, expanding trial sites across Europe and the U.S. and aiming for first data in 2026. Unlike approved thrombolytics that target a single pathway, TGD001 leverages the ubiquitous presence of VWF to enable broad clot dissolution. TargED has raised over €60 million in Series A financing to date and also received a blended-finance grant from the European Innovation Council Accelerator in 2025. The fresh capital strengthens its balance sheet and accelerates clinical development toward demonstrating proof-of-concept in multiple life-threatening indications.

Participated · Seed · Apr 2025

Avidicure is pioneering an entirely new multifunctional antibody modality, branded AVC-Boosters, with broad applicability in oncology. The AVC-Boosters are dual agonistic, multifunctional and avidity-engineered antibodies designed to elicit orchestrated innate and adaptive immune responses as targeted cancer monotherapies. The company leverages a fully owned proprietary platform combining decades of antibody engineering, in silico protein design capabilities, and immunology expertise. Through AVC-Booster plug-and-play functionality, multiple products can be developed from the platform. Avidicure's lead product, AVC-S-101, is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple other indications. The founding management team is led by CEO Arthur Lahr, with Dirk De Naeyer (COO), Robert Friesen (CSO) and Govert Schouten (CBO). Avidicure raised $50m in seed financing to advance its programs; no operating metrics were reported in the article.

Participated · Equity · Feb 2025

Sirius Medical develops the Sirius Pintuition surgical navigation platform and GPSDetect software to enable wire‑free localization for breast‑conserving surgery. The Pintuition system is CE marked and FDA cleared and has been praised by breast cancer surgeons. The company traces its roots to the Netherlands Cancer Institute and reports adoption in over 250 centers and 35,000 procedures globally. Sirius Medical is focused on improving usability and extending applications of its platform. The company announced it secured €10M in additional scale‑up funding to support product development and global expansion. The investment will also be used to bolster sales infrastructure and enter new markets. Sirius Medical develops Pintuition, a surgical marker navigation system that gives surgeons real-time distance and directional guidance to locate tumors. The company is led by CEO Bram Schermers and is focused on improving care for cancer patients by enabling precise and efficient tumor removal. Pintuition is active in over 100 centers with more than 5,000 procedures across Western Europe and the US. Sirius experienced revenue growth in 2022 and has built an international sales network in Europe and the USA. The company plans to use new funding to accelerate worldwide growth of Pintuition, support further product development, and expand commercial roll-out. Sirius Medical has commercially launched the Sirius Pintuition System, a localisation platform designed to help surgeons pinpoint breast tumours during surgery. The system is CE marked and Sirius is pursuing FDA clearance. The Pintuition seed can be placed up to 180 days before surgery and the intraoperative probe gives real-time feedback and directional guidance to marked tissue. Sirius positions Pintuition as an easy-to-use, affordable alternative to metal anchor wires and radioactive seeds, aiming to improve hospital workflow and surgical accuracy. The company is developing a pipeline of complementary products and indications alongside the commercial rollout. Management says recent funding will be used to execute growth plans and advance the product pipeline.

Participated · Series B · Dec 2024

Citryll, based in Oss, The Netherlands, is advancing a novel approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs). Its lead asset, CIT-013, is a first-in-class monoclonal antibody with a dual mechanism of action that enhances clearance of existing NETs and inhibits formation of new NETs. The company says this approach could create a new class of therapeutics with broad applications across conditions such as rheumatoid arthritis and hidradenitis suppurativa. Citryll is led by CEO Eduardo Bravo. The company intends to use the funds from its Series B to enable next steps in the clinical development of CIT-013. The technology aims to address a fundamental component of the inflammatory process that has not yet been therapeutically targeted. Citryll develops CIT-013, a therapeutic antibody designed to inhibit formation of neutrophil extracellular traps (NETs) and NETosis. The company intends to use CIT-013 to treat autoimmune and NET-driven conditions, including lupus, organ damage from sepsis, asthma and NET-induced thrombosis. Citryll says CIT-013 does not broadly target inflammation or acquired immunity but instead extinguishes NET-derived autoantigens and toxic, prothrombotic and proinflammatory components. Proceeds from the fundraise will advance the preclinical and clinical development and manufacturing of CIT-013. The programme’s preclinical development and manufacturing were accelerated in 2019 via a first closing with existing investors, and the program was on track to reach the clinic in 2021. Citryll describes its team as world leaders and pioneers in the NETosis space. The company is based in Oss, the Netherlands, and was founded by ModiQuest B.V. together with CEO Helmuth van Es and CSO Renato Chirivi. Citryll develops tACPA, a class of antibodies that inhibit NETosis by binding N‑terminal citrullinated histone epitopes essential for NET formation, acting downstream of the PAD‑dependent citrullination pathway. The company’s approach aims to extinguish sources of autoantigens and NET‑derived toxic molecules without broadly suppressing inflammation or acquired immunity. Citryll targets autoimmune and other diseases driven by NETs, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Proceeds from its recent financing will be used to advance pre‑clinical and clinical development of the tACPA therapeutic. Citryll was founded by ModiQuest B.V., CEO Helmuth van Es, and CSO Renato Chirivi, and is based in Oss, the Netherlands. The company positions tACPA as a first‑in‑class therapeutic innovation addressing significant medical needs where NET formation plays a crucial pathogenic role.